BIOMAT Database Logo BIOMAT Database Logo

Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. 1995

G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Department of Hematology/Oncology, University Hospital Göttingen, Germany.

To determine the value of aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis (IPA), we initiated a prospective randomized multicenter trial. The scheduled intent-to-treat interim analysis included 115 patients (30%) with prolonged neutropenia after chemotherapy for acute myeloid leukemia, acute lymphoblastic leukemia/high-grade non-Hodgkin's lymphoma, or solid tumors undergoing autologous stem cell transplantation. Sixty-five patients had been randomized to receive prophylactic aerosol amphotericin B inhalations at a dose of 10 mg twice daily (group A); for the remaining 50 patients no aerosol amphotericin B prophylaxis was used (group B). No serious side effects from amphotericin B inhalations occurred, but coughing (54%), bad taste (51%), and nausea (37%) caused early cessation of aerosol amphotericin B prophylaxis in 23% (15/65) of courses. In group A, the incidence of proven, probably, or possible IPA was 5% (3/65) as compared with 12% (6/50) in group B (p > 0.05). Microbiologically documented bacterial pneumonias were observed in 5/65 (8%) patients in group A and in 1/50 (2%) patients in group B (p > 0.05). Thus, no reduction in incidence of IPA from use of prophylactic aerosol amphotericin B inhalations was found in this interim analysis. As there were no serious side effects from aerosol amphotericin B prophylaxis, accrual in the study will continue for a total of 380 patients.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008172 Lung Diseases, Fungal Pulmonary diseases caused by fungal infections, usually through hematogenous spread. Fungal Lung Diseases,Pulmonary Fungal Infections,Pulmonary Fungal Diseases,Fungal Disease, Pulmonary,Fungal Diseases, Pulmonary,Fungal Infection, Pulmonary,Fungal Infections, Pulmonary,Fungal Lung Disease,Lung Disease, Fungal,Pulmonary Fungal Disease,Pulmonary Fungal Infection
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis.
June 1993, Antimicrobial agents and chemotherapy,
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients.
May 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Treatment of invasive pulmonary aspergillosis in neutropenic patients by additional bronchoscopic amphotericin B instillation.
January 2007, Respiration; international review of thoracic diseases,
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Case reports. Invasive pulmonary aspergillosis in non-neutropenic patients treated with liposomal amphotericin B.
January 1999, Mycoses,
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
February 2011, Journal of chemotherapy (Florence, Italy),
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients.
June 1991, The American journal of medicine,
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
[Invasive pulmonary aspergillosis in non-neutropenic patients].
September 2016, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.
May 1994, Antimicrobial agents and chemotherapy,
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Surgical management of invasive pulmonary aspergillosis in neutropenic patients.
November 1997, The Annals of thoracic surgery,
G F Behre, and S Schwartz, and K Lenz, and W D Ludwig, and H Wandt, and E Schilling, and V Heinemann, and H Link, and A Trittin, and O Boenisch
Apparent pulmonary mycetoma following invasive aspergillosis in neutropenic patients.
February 1988, Thorax,
Copied contents to your clipboard!